Conţinutul numărului revistei |
Articolul precedent |
Articolul urmator |
635 4 |
Ultima descărcare din IBN: 2020-06-20 18:14 |
Căutarea după subiecte similare conform CZU |
053.32-022.7-007.17-24./614.47:616.233 (1) |
ОБЩИЙ ОТДЕЛ. НАУКА И ЗНАНИЕ. ИНФОРМАЦИЯ. ДОКУМЕНТАЦИЯ. БИБЛИОТЕЧНОЕ ДЕЛО. ОРГАНИЗАЦИИ. ПУБЛИКАЦИИ В ЦЕЛОМ (10229) |
Заболевания дыхательной системы (747) |
SM ISO690:2012 СЕМЕРИКОВ, Владислав, ЗУБОВА, Елена, ЛОШКАРЕВА, Вера, СОФРОНОВА, Людмила, ПЕРМЯКОВА, Мария. К вопросу вакцинопрофилактики пневмококковой инфекции среди недоношенных детей с бронхолегочной дисплазией. In: One Health and Risk Management, 2020, nr. 1(1), pp. 27-35. ISSN 2587-3458. DOI: https://doi.org/10.5281/zenodo.3700973 |
EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
One Health and Risk Management | |||||
Numărul 1(1) / 2020 / ISSN 2587-3458 /ISSNe 2587-3466 | |||||
|
|||||
DOI: https://doi.org/10.5281/zenodo.3700973 | |||||
CZU: 053.32-022.7-007.17-24./614.47:616.233 | |||||
Pag. 27-35 | |||||
|
|||||
Descarcă PDF | |||||
Rezumat | |||||
Introduction. Bronchopulmonary dysplasia (BPD) is the most common chronic lung disease among children of the first year of life, especially children born prematurely with extremely low and very low body weight. Material and methods. To estimate the number of children born alive in Perm Territory between 2015 and 2017, official statistics data were used. Experimental epidemiological studies were used to assess safety, reactogenicity, immunogenic activity and preventive efficacy of the Prevnar 13 vaccine when immunizing preterm infants with bronchopulmonary dysplasia under prospective controlled randomized clinical observation. Results. There were 29 premature infants with bronchopulmonary dysplasia under observation, the control group comprised 29 unvaccinated premature infants with BPD and 30 full-term infants. The PCV 13 vaccination of preterm infants with BPD established good tolerance, poor reactogenicity (17.2±0.57%) and vaccine tolerance like full-term infants (16.5±0.55%), high safety profile, high immunogenic properties (seroconversion – 93.1%, seroconversion factor – 5.5). Evaluation of immunogenic activity among children with BPD vaccinated with the PCV 13 vaccine revealed high immunological efficacy compared to unvaccinated healthy children. Conclusion. The need for vaccination of premature babies with BDL against pneumococcal infection has been scientifically substantiated. The study has confirmed safety, poor reactogenicity, high immunogenic activity and preventive efficacy of the Prevenar 13 vaccine among premature babies with BDL under the conditions of the catamnesis department of the perinatal center within the follow-up monitoring of vaccinated infants over three years. |
|||||
Cuvinte-cheie PCV13 vaccine, pneumococcal infection, bronchopulmonary dysplasia, vaccin VPC13, infecție pneumococică, displazie bronhopulmonară |
|||||
|